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Abstract
Background: Gene silencing in the retina using RNA interference could open broad possibilities for functional
studies of genes in vivo and for therapeutic interventions in eye disorders. Therefore, there is a considerable
demand for protocols to deliver siRNA into the vertebrate retina. In this work we explored a possibility to deliver
synthetic 21 bp siRNA into the mouse retina after intravitreal application using a non-viral carrier.
Methods: Fluorescently labelled synthetic 21 bp siRNA duplex was combined with Transit-TKO transfection reagent
and injected intravitreally into adult mice eyes. Eyes cryostat sections and whole mount retinas were prepared
24-48 h post-injection, stained with either Hoechst 33342 (cell nuclei) or immunostained with anti-GFAP antibody
(astroglia cells marker). Distribution of fluorescent siRNA signal in the retina was investigated.
Results: Single intravitreal injection of as little as 5 ng of siRNA combined with Transit-TKO transfection reagent by
a modified protocol provided robust and non-toxic delivery of the siRNA into the retina. However, siRNA
accumulation was predominantly confined to ganglion cells layer as analysed 24 h post-injection. Furthermore,
siRNA containing particles were localized along GFAP cytoskeleton of retinal astroglial cells hinting on intracellular
localization of the siRNA
Conclusions: In this work we demonstrated that siRNA can be efficiently delivered into the vertebrate retina in
vivo with low-toxicity using a non-viral carrier, specifically Transit-TKO transfection reagent. However, the capacity
of siRNA delivered by our protocol to induce gene silencing in the retina has to be further evaluated. Our report
could raise a closer look on Transit-TKO transfection reagent as a promising siRNA carrier in vivo and be of interest
for the researchers and companies who work on development of ocular RNAi techniques.
Background
The technology of RNA interference (RNAi) offers the
perspective for selective and on demand silencing of
gene expression. One of the critical factors that limit the
experimental and therapeutic application of RNAi
in vivo is the ability to deliver intact siRNA efficiently.
Although RNAi technology has been successfully
demonstrated for cell lines and primary cultures, deliv-
ery of siRNA in mammalian tissues in vivo provides a
significant challenge [1]. Particular difficulties have been
associated with non-viral gene transfer into the retina
in vivo [2]. One of the challenges is to overcome the
inner limiting membrane, which impedes the transfec-
tion of the retina [3,4]. Additionally, negatively charged
sugars of the vitreous have been shown to interact with
positive DNA-transfection reagent complexes promoting
their aggregation, impeding diffusion and cellular uptake
[5,6]. To date reports describing ocular siRNA applica-
tions are amounting. However, strategies are divergent
and the outcome is highly variable. Some experiments
showed successful knock-down after injection of naked
unmodified or nuclease protected siRNA to a number of
tissues including retina. Intravitreal application of
“naked” stability modified siRNA directed against vascu-
lar endothelial growth factor (VEGF) or VEGF receptor
1 suppressed ocular neovascularisation in rats [7]. How-
ever, a phenomenon of sequence independent suppres-
sion of retinal neovascularisation by siRNAs has been
recently reported by Kleinmann and colleagues [8].
Furthermore, some reports indicate that naked 21-nt
siRNA can not be internalized into the cells unless cell-
permeating moieties are used [9]. Moreover, besides
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poor cellular uptake, unprotected siRNA is prone to
relatively rapid degradation in the vitreous [10]. A com-
bination of siRNA with common commercial transfec-
tion reagents including Lipofectamine 2000 [11] and in
vivo jetPEI [12] proved to be successful for shRNA
encoding plasmid DNA delivery into the retina through
intravitreal application. Transit-TKO transfection
reagent has been previously used as a carrier to deliver
siRNA subretinally [13] and subconjuctivally [14]. In
this work, we have tested the feasibility of using Transit-
TKO transfection reagent for siRNA delivery into the
mouse retina after intravitreal injection.
Methods
Intravitreal injections
The intravitreal injection procedure had a proper per-
mission of the Ruhr University Bochum according to
German animal protection law. Wild-type mice of
C57BL/6 strain (6 month old) were anesthetized by
intraperitoneal injection of ketanest/xylazine (ketanest,
100-125 mg/kg; xylazine, 10-12.5 mg/kg). Intravitreal
injections were performed under a dissecting micro-
scope with a 32 gauge needle attached to a 5 μl glass
syringe (Hamilton, Reno, USA). The needle was posi-
tioned 1 mm posterior to the limbus and 1 μl of the
solution was slowly (3-5 seconds) injected into the vitr-
eous chamber of the eye. A 20 second interval was kept
before removing the needle.
Preparation of Transit TKO-siRNA complexes
Transit-TKO transfection reagent was purchased from
Mirus Bio (Madison, USA). For monitoring the transfec-
tion efficacy we used non-specific 21 base pairs long
DY-547 labelled siRNA duplex (siGlo) provided by
Dharmacon (Lafayette, USA). The optimised protocol
was as follows: 0,1 μg (7,5 pmol) of siRNA was com-
bined with 4,5 μl of Transit-TKO in 50 μl of H2O and
incubated for 20 min at RT. Water was used as a sol-
vent to minimize the size of the transfection particles
and to prevent aggregates which may impair penetration
through the inner limiting membrane into the retina.
Afterwards, the solution was evaporated under vacuum
and precipitate was dissolved in either 5 μl or 20 μl
H2O shortly before injection.
Retina cryostat sections
Mice were anesthetized by asphyxiation in CO2 and
euthanized by cervical dislocation 24 h after intravitreal
injection. The eyes were enucleated, covered in tissue
freezing medium (Leica, Nussloch, Germany) and frozen
in 8% methylcyclohexan in 2-methylbutan (v/v;-60°C).
Sagittal cryosections, 12 μm thick, were prepared and
placed on Superfrost Plus slides (Menzel-Glaser,
Braunschweig, Germany). Sections were dried for 60
min at 40°C and fixed in 4% paraformaldehyde for 10
min. For staining cells nuclei cryosections were incu-
bated in 1:10,000 of Hoechst 33342 dye (Promega,
Madison, USA) for 20 min, rinsed in PBS and mounted
with ProLong Antifade kit (Molecular Probes). Fluores-
cent images were analysed by fluorescent microscopy.
Immunohistochemistry on whole mount retinas
Mice were anesthetized by asphyxiation in CO2 and
euthanized by cervical dislocation 48 h after intravitreal
injection. The eyes were enucleated; retinas were dis-
sected under a binocular using fine forceps and fixed in
4% para-formaldehyde in PBS at 4°C for 2 hrs. Following
fixation, retinas were rinsed in PBS and incubated in
blocking solution containing 10% normal goat serum
diluted in PBS with 1% Triton-X-100 for 2 hrs at room
temperature. Afterwards retinas were incubated with
mouse monoclonal anti-GFAP antibodies (1:100)
(Sigma-Aldrich, St. Louis, USA) in PBS with 0,1%
Tween 20 for 2 days at 4°C. Retinas were rinsed three
times in PBS for 30 min at room temperature, followed
by an overnight incubation at 4°C with secondary anti-
body (Alexa Fluor® 546 red goat anti-mouse, Molecular
Probes, Leiden, Netherlands) at 1:1,000 dilution in PBS
containing 2 mg/ml of bovine serum albumin. Retinas
were washed 5 times for 30 min each in PBS and
mounted (ganglion cell layer side up) with ProLong
Antifade kit (Molecular Probes). The specimen were
analysed by confocal microscopy (Zeiss, LSM 510 Meta).
Results
In this work we explored Transit-TKO transfection
reagent as a carrier to deliver siRNA into the mouse
retina in vivo through intravitreal injection. As a base
protocol for Transit-TKO/siRNA formulation we used
the manufacturer’s instructions for in vitro transfection.
However, we further modified siRNA complexation pro-
cedure in a way to reduce the average size of the
siRNA-reagent complexes, therefore increasing their
mobility in the vitreous. For that purpose we 1) com-
bined siRNA with Transit-TKO transfection reagent in
water (instead of serum free media) in order to reduce
the ionic strength of the solution; 2) performed com-
plexation of siRNA with the reagent initially in a diluted
volume (50 μl) with subsequent concentration by speed
vacuum evaporation. The concentration of the siRNA/
Transit-TKO solution was required due to the fact that
the maximum volume of 1 μl could be injected into the
mouse vitreous at once.
After single intravitreal injection of as little as 20 ng of
siRNA combined with Transit-TKO reagent robust
transfection of the retina was observed. Fluorescent sig-
nals of siRNA were reproducibly detected in the gang-
lion cells layer (GCL) of the retina as aggregates of
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variable sizes 24 h post-injection (Fig. 1A). Significantly
fewer aggregates were found in the inner plexiform and
inner nuclear layers suggesting that siRNA uptake was
limited to the innermost cell layer 24 h post injection.
However, we did not analyze the dynamic of siRNA
penetration into the retina in later time points. In sec-
tions of whole mount retina preparations a typical distri-
bution of siRNA in the ganglion cells layer with
fluorescent particles frequently located close to the cell
nuclei was observed (see arrows; Fig. 1B). However,
siRNA accumulation was not uniform along the retina,
revealing regions of high and low transfection (Fig. 1C
indicated by oval regions).
Next, we investigated intracellular localization of
siRNA in the retinal astrocytes which reside on the
boundary of ganglion cells layer and the vitreous. Whole
mount retinas prepared 48 h after single intravitreal
injection of 5 ng siRNA/Transit-TKO were stained for
astrocytes specific glial fibrillary acidic protein (GFAP)
(Fig. 2). siRNA particles were localized within or along
the astrocytes cell bodies and processes hinting on their
intracellular localization (Fig. 2 indicated by arrows). We
did not measure the damage of the retina after intravi-
treal injection of 20 ng of siRNA. However, no altera-
tions in GFAP cytoskeleton was observed when using 5
ng of siRNA per injection suggesting that retinal astro-
cytes were not impaired by the treatment.
Discussion
We explored a number of possibilities to deliver syn-
thetic 21 bp long siRNA duplex into the mouse retina
after single intravitreal injection. We have found, how-
ever, that injecting up to 5 μg of naked fluorescently
labelled siRNA into the vitreous did not provide any
visible siRNA accumulation in the retina (as analysed 24
h post-injection). This can be explained by rapid degra-
dation of unprotected siRNA in the vitreous. Mixing
siRNA with common cationic lipids-based transfection
reagents including siLentFect (BioRad) and Oligofecta-
mine (Invitrogen) in different siRNA/reagent propor-
tions also did not induce any visible siRNA uptake by
retinal cells after intravitreal injection (data not shown).
However, both of these transfection reagents provided
robust penetration of siRNA into mammalian cells in
culture. These results were consistent with previous
reports indicating that the efficient transfection of the
retina is difficult to achieve [2-6]. Among the difficulties
are the inner limiting membrane that separates vitreous
cavity from ganglion cells layer and the vitreal fluid that
constitute a non-permissive environment for the trans-
fection of the retina with cationic lipids.
Transit-TKO transfection reagent mixtures with
siRNA has been previously reported to successfully
knockdown genes in pulmonary tissue after intranasal
delivery [15], retinal pigmented epithelium after subret-
inal injection [13] and corneal fibroblasts after subcon-
juctival injection [14]. This motivated us to test this
approach to deliver siRNA through intravitreal applica-
tion - more challenging and at the same time less inva-
sive route for the retina transfection. Our modified
protocol mediated robust delivery of the siRNA through
the inner limiting membrane into the retina. Further-
more, siRNA containing particles colocolized (or resided
in a close proximity) with astrocytic GFAP cytoskeleton
and cells nuclei indicating intracellular localisation.
We had also tested the ability of siRNA delivered by
our protocol to induce silencing of the gap junction pro-
tein Cx43. Cx43 is highly expressed by retinal astrocytes
- the layer that resides in the vitreal surface of the retina.
However, analysis of Cx43 mRNA level performed by
Figure 1 Intravitreal injection of siRNA. A. Fluorescent micrograph of a cryostat section and B), C) whole mount retinas prepared 24 h after
single intravitreal injection with 20 ng fluorescent siRNA (red) combined with Transit-TKO in low ionic environment. Note, the prominent
localization of siRNA in the ganglion cells layer (GCL) of the retina. Arrows indicate the examples of cytoplasmic accumulation of siRNA near to
cells nuclei. Low and highly transfected regions of the retina are marked by ovals (I, II). Cells nuclei were counterstained with Hoechst (blue).
Scale bar = 20 μm.
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qRT-PCR on whole dissected retinas did not reveal any
detectable Cx43 knockdown 96 h after injection of
Cx43 directed siRNA (data not shown). It is important
to mention, that in our hands the area of the retina
containing fluorescent signals of siRNA varied signifi-
cantly from injection to injection and was not greater
than 30% (usually 10-30% as analyzed by subjective
assessment of at least N = 12 eyes). Therefore it
remains unclear whether the absence of Cx43 knock-
down in our tests can be attributed to the inability of
siRNA delivered by our formulation protocol to med-
iate functional effect in the retina. We assume that our
protocol has still too preliminary efficacy to assess
siRNA functionality. We performed intravitreal injec-
tion manually, without a help of a stereotactic device.
Although this approach is valuable for fast screening
of a large number of different siRNA/reagent mixtures,
more delicate control of intravitreal injections could
require achieving uniform and complete retina trans-
fection. Thus, elimination and distribution of com-
pounds in the vitreous have been previously described
[16,17]. In rodents, the procedure for intravitreal
injection is additionally complicated by the large lens
size and relatively small vitreous cavity. Therefore,
extraocular loss of injected solution can be significant
and increases for higher injected volumes, with larger
standard deviations [17].
Conclusions
In this work we developed a modified protocol for the
formulation of siRNA with Transit-TKO transfection
reagent. siRNA combined by our protocol was capable
to penetrate through the inner limiting membrane into
the retina and accumulated in ganglion cells layer
including retinal astrocytes. However, more delicate
control of the conditions for intravitreal injections is
needed to reduce treatment variability and to increase
uniformity of transfection. Nevertheless, our formulation
protocol can serve as a starting point for developing
more uniform and complete siRNA transfection of the
retina in vivo. Our report could raise a closer look on
non-viral carriers for intraocular siRNA delivery and be
of interest for the researchers and companies who work
on development of ocular RNAi techniques.
Figure 2 Localisation of siRNA in retinal astrocytes. Confocal micrographs obtained after anti-GFAP (green) immunostaining of whole mount
retinas performed 48 h after single intravitreal injection of 5 ng fluorescently labelled siRNA (siGlo, red) combined with Transit-TKO. The pictures
in A-C show a single plane through the vitreal surface of the retina highlighting prominent sides of siRNA localization. A - GFAP; B - siRNA
(siGlo); C - Merged. The localization of siRNA along GFAP processes and cell bodies is indicated by arrows (enlarged in frames 1, 2, 3).
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